drugset / Trial / NCT02862431
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety and tolerability of JNJ-64565111 in adult Men and Women (of non-child bearing potential) with Type 2 Diabetes Mellitus.
Timeline
- Start
- 2016-07-12
- Primary completion
- 2016-11-29
- Completion
- 2016-12-05
Outcome
Outcome not reported
Stopped: “manufacturing-related issues”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efinopegdutide | Protein / enzyme biologic | 2.5 mmol | Subcutaneous |
| Subject | Efinopegdutide | Protein / enzyme biologic | 3 mmol | Subcutaneous |
| Subject | Efinopegdutide | Protein / enzyme biologic | 3.5 mmol | Subcutaneous |